Modulation of fibrin clot formation by human serum amyloid P component (SAP) and heparin by unknown
MODULATION  OF  FIBRIN  CLOT  FORMATION  BY  HUMAN 
SERUM  AMYLOID  P  COMPONENT  (SAP) AND  HEPARIN* 
BY CECILIA S.  L.  Ku* AND BARRY A. FIEDEL  § 
From the Department of Immunology~Microbiology, Rush Medical Center, Chicago, Illinois 
60612 
Serum amyloid P component (SAP) l is a  normal plasma glycoprotein in man 
with a circulating concentration of ~40 gg/ml (1), and is probably identical to 
the amyloid P  component associated with  most forms of amyloid deposits (2). 
Ligands identified thus far for SAP include agarose (3-5), heparin (6, 7), heparin 
sulfate bound to Sepharose 4B (8),  isolated amyloid fibrils (9),  zymosan (9,  10), 
iC3b  and  C4  binding  protein  (11-13),  and  fibronectin (14).  Recently, it  was 
shown that an apparent tissue counterpart of SAP is an integral constituent of 
normal vascular basement membranes (15),  and is distributed throughout the 
peripheral microfibrillar mantle of elastic fibers in normal skin and blood vessels 
(16). Moreover, supraphysiological concentrations of SAP (150-300 #g/ml) have 
been reported to affect blood coagulation (17). 
SAP-like proteins have been isolated from the sera of elasmobranchs, teleost 
fish,  amphibia,  and  mammals  (18).  These  proteins  resemble  human  SAP  in 
partial amino acid sequence (reviewed in reference 19) and calcium-dependent 
ligand  binding  specificity.  The  stable  conservation  in  SAP  during  much  of 
vertebrate evolution implies that SAP may have an important function(s). Indeed, 
SAP  is  a  member  of a  super  family of structurally  related  proteins  termed 
pentraxins (20) and shares a number of physiochemical properties with the acute- 
phase reactant, C-reactive protein (CRP), although unlike CRP,  SAP is not an 
acute phase reactant in man. 
The  present  study systematically investigates  the effect(s) of SAP on  blood 
coagulation, and provides evidence for an interaction between SAP and certain 
major components of the coagulation system. A  potential function for SAP in 
host defense is suggested. 
Materials and Methods 
Preparatio~  of Normal Plasmas.  Blood obtained from healthy volunteers was antico- 
agulated with acid-citrate dextrose (22°C), platelet-rich plasma (PRP) obtained, and the 
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final platelet-free plasma pools prepared from PRP by centrifugation at 2,000 g for 20 
rain (11, 21).  The pools were stored at -20°C before use. 
Isolation of Serum Amyloid P Component.  SAP was isolated (4, 21) as previously described 
with  final  preparations  dialyzed  against  1,000  volumes  of  buffered  saline,  pH  7.2; 
concentration  was determined by radialimmunodiffusion (RID), absorbance at 280  nm 
using  an  average E~m  =  18.2  (22)  and  Lowry analyses  (23).  Purity  was  assessed  by 
polyacrylamide gel  electrophoresis (PAGE)  in  the  presence  of sodium  dodecyl sulfate 
(SDS) and urea (20, 21, 24).  Application of 100 ~g SAP to SDS-PAGE resulted in a single 
detectable protein species; (sensitivity: <<2 ~g protein; purity: ->98%). To further assure 
purity, we labeled SAP with 125],  as described (21), and re-analyzed the preparations with 
SDS-PAGE: >99% of the radiolabel was found associated with an electrophoretic species 
corresponding to the subunit molecular weight of SAP in SDS-PAGE. C-reactive protein 
(CRP),  an  acute  phase  homologue  of  SAP  in  man  (20),  was  not  detected  in  these 
preparations of SAP as adjudged by RID; SAP was applied at concentrations of 600-1,200 
ug/ml,  resulting in a  nominal sensitivity of <1  ug CRP antigen per 200  ug SAP.  The 
purified SAP was filter sterilized (Millipore Corp., Boston, MA) and stored at 4°C. The 
average yield was 44%. 
Activated Thrombofax Clot Time (Activated Partial  Thromboplastin Time; APTT).  Plasma 
(0.2  ml) was  pipetted  into a  glass tube at  37°C.  Thrombofax Reagent  (0.2  ml;  Ortho 
Diagnostics, Raritan, N  J)and 0.14 ml of standard buffer (0.05 M Tris-HCl, 0.15 M NaC1, 
pH 7.4) were added and incubated for 5 min, the fibrin clot induced by recalcification, 
and the clot time determined (25, 26).  In experiments evaluating the effect of SAP and/ 
or  heparin  on  Activated  Thrombofax clotting  time,  SAP  was premixed  with  buffer; 
heparin (beef lung,  obtained from the  Upjohn  Pharmaceutical Co.,  Kalamazoo, MI, as 
drug #U-1394, Lot #730-EH) was added  1 min before the addition of CaCI~. 
Tissue Thromboplastin Clot Tbne (Prothrombin Time).  To plasma (0.2 ml) prewarmed to 
37 °C in a plastic tube was added 45 #1 of standard buffer or SAP, and 40 ~1 of heparin 
or saline, and the mixture was incubated (1 min; 37°C); next, 90 ~1 each of thromboplastin 
reagent and CaCI2 (at 20 raM) were added and clot time was recorded. 
Russell's Viper Venom (RVV) Clot Time (27).  Standard buffer (0.3 ml), or SAP, was mixed 
with 200 #1 prewarmed plasma and incubated (1 rain; 37 °C). Heparin (25 ul) and additional 
standard buffer (35 #1) were then added, and after 1 min, 105 tA each of RVV (prewarmed 
at 37°C) and 20 mM CaCl~ were introduced into the tube. 
Activated Factor X Clot Time (from Mann; 28).  Before the addition of 50 #1 Factor Xa to 
a plastic tube, 0.1  ml of plasma and 0.35 ml standard buffer were incubated at 37°C for 
1 rain (in  test samples, SAP and/or heparin were also included).  Exactly 90 s following 
Factor Xa addition, 0.1  ml was transferred into a second tube at 37°C; 20 s later, 0.1  ml 
of 20 mM CaCI,~ was added to the second tube and clot formation initiated by addition of 
0.2 ml plasma-cephalin. 
Throlnbbl Clot Time (29).  200  #1  plasma (37°C)  was mixed  for  1 min with 0.15  ml 
standard buffer containing various amounts of SAP/heparin and 0.1  ml saline. Next, 50 
ul thrombin was added and the clot time measured. 
Fibrinoge~ / Thrombb~ Clotting Assay.  Various concentrations of thrombin were added to 
human fibrinogen (2 mg/ml) in the presence of different amounts of SAP/heparin. Total 
volume was 0.5 ml in  10 mM Tris-saline buffer containing 2 mM CaCI~, pH 7.4 (Tris- 
Ca++). 
RadiobmmmoassayofFibrmopeptide  A (30).  A radioimmunoassay (RIA) for measuring 
fibrinopeptide A (FPA) was purchased from Mallinckrodt (St. Louis, MO). Fibrinopeptide 
A was generated as follows: 0.1  ml of a plasma pool was pipetted into a plastic microfuge 
tube and  diluted  to 0.45  ml with  Tris-Ca  ++  buffer.  FPA  release  from fibrinogen  was 
initiated  by addition  of 50  ul  thrombin  (0.1-0.2  U/ml);  1  rain  later,  the  tubes  were 
centrifuged (1 rain; 4°C), and the supernatant aspirated and mixed with 1 ml of Bentonite 
slurry.  The supernatant containing FPA was re-collected and tested.  To determine the 
effects of SAP and heparin on the production of fibrinopeptide A, SAP and heparin were 
preincubated with the diluted plasma sample before the thrombin addition. Fibrin Polwnerization. 
of Hall and "Slayter (31). 
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Fibrin polymerization was performed according to the method 
Results 
Effect of SAP on Extrinsic,  Intrinsic, Common, and Terminal Phases of the Coagulation 
Cascade.  SAP  (5-125  #g/ml)  had  no  effect on  the  clot  times  generated  by 
activating  the  intrinsic  pathway  with  Activated  Thrombofax  reagent  in  the 
absence of heparin (Fig.  1). However, in the presence of heparin, which by itself 
had only a  minor anticoagulant effect, SAP greatly prolonged the onset of clot 
formation.  No clot formation  was observed when  the SAP concentration used 
was increased beyond 100 ug/ml. 
In the absence of heparin,  SAP (10-60  ug/ml) did not affect the fibrin clot 
time obtained by initiating the intrinsic coagulation pathway with tissue throm- 
boplastin  reagent,  as depicted in  Fig.  2.  However, in  the presence of heparin, 
SAP  again  greatly  prolonged  onset  of clot  formation;  no  clot  formation  was 
observed when the SAP concentration used exceeded 60 #g/ml. 
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FIGURE  1.  The comparative effect of SAP on clot times (+ SD) generated  by Activated 
Thrombofax reagent in normal plasma in both the presence or absence of heparin. In Figs. 
1-4, the concentration of heparin used was determined by pretitration of each plasma pool 
during the respective experiment.  The concentration  of heparin  was  that  amount  which 
increased clotting  times by  20-25  s above baseline levels in  the absence of SAP. Final 
concentrations ranged between 0.4 and 1.0 NIH U/ml heparin. 770  SERUM  AMYLOID  P  COMPONENT  AND  BLOOD  COAGULATION 
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FIGURE 2.  Effect  of  SAP on clot times (+ SD) generated  by Tissue Thromboplastin  in normal 
plasma both in the presence or absence of heparin (see Fig. 1). 
The potent anticoagulant activity of various concentrations of SAP in the RVV 
assay in the presence of heparin is shown in Fig. 3. As RVV initiates the common 
coagulation pathway at the level of Factor X,  this result, together with results 
from Figs.  1 and 2, show that in the presence of heparin each the intrinsic and 
extrinsic pathways were affected by small amounts of SAP (<40 txg/ml). Similar 
studies revealed that SAP alone (10-45 ~g/ml) did not affect clot times generated 
by the  direct addition of activated  Factor Xa  and cephalin.  However,  in  the 
presence of heparin, SAP again exhibited an anticoagulant activity. 
To test the effect of SAP and heparin on the terminal stage of the coagulation 
system, a  thrombin time assay was performed. Fig. 4  demonstrates that in the 
absence of heparin, SAP (5-35 #g/ml) failed to prolong the clot time. However, 
SAP prolonged clot times in presence of heparin. The threshold concentration 
of SAP required in this system was found to be  20-25  ug/ml, and resulted in 
the absence of clot formation. 
These  results  demonstrated  that  in  the  presence  of minimal  amounts  of 
heparin,  fibrin  clot  times  generated  by  activation  of both  the  intrinsic  and 
extrinsic pathways were prolonged by SAP, with major sensitivity to the presence KU AND FIEDEL  771 
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FIGURE 3.  Effect of SAP on clot times (-+ SD) generated by Russell's Viper Venom-cephalin 
in the presence or absence of heparin (see Fig. 1). 
of SAP observed at the distal level of the coagulation system. Additional studies 
ruled out that  the anticoagulant synergism between SAP and heparin was the 
result of potentiation of anti-thrombin III (AT III) activity as compared to the 
effect of heparin alone; this inhibition of clot formation also occurred in plasma 
genetically deficient in coagulation Factor XIII, negating an affect upon Factor 
XIIIa-driven  trans-amidation  reactions as  the  mechanism of action.  SAP and 
heparin also failed to alter the euglobulin clot lysis time (32) or the kinetics of 
125I-fibrin(-ogen)  release from fibrin clots digested with plasmin (Fig. 5; reference 
32). Thus, the prolongation of fibrin clot times by SAP and heparin was not a 
reflection of an enhanced rate of fibrinolysis. 
Evaluation7 of the Role of SAP i~ the Co~versio~ Process of Fibrinogen to Fibrin.  The 
terminal phase of coagulation, i.e. the conversion of fibrinogen to fibrin (34), is 
classically described as composed of several reactions (35). First, thrombin cleaves 
two pairs of peptides from fibrinogen, termed fibrinopeptide A and B (released 
from the N-terminal of the a  and/3 chains, respectively; reference 36); second, 
upon  release  of these  peptides,  polymerization  of the  fibrin  monomer  units 
occurs  spontaneously.  Table  I  illustrates  the  effects of SAP  and  heparin  on 
thrombin clot times and the release of fibrinopeptide A  (FPA) as a  marker of 772  SERUM AMYLOID P COMPONENT AND BLOOD COAGULATION 
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FIGURE 4.  The comparative effect of SAP on clot times (_  SD) generated by addition of 
thrombin to normal plasma in the presence or absence of heparin (see Fig. 1). 
fibrinogen cleavage in plasma, and the proteolytic activity of thrombin. 
SAP (50 #g/ml) did not affect the proteolytic action of thrombin measured 
either as release of FPA or liberation of p-nitroaniline from the chromogenic 
substrate;  when compared with controls,  50 #g/ml SAP also failed to demon- 
strate  any  anticoagulant  activity.  However,  SAP  at  200  /~g/ml  reduced  the 
production of FPA to  75%  without any direct inhibition of thrombin activity, 
and this was associated with a prolonged clot time. Heparin delayed the thrombin 
clot time from 23.9 to 48.2 seconds, which correlated with the reduction of FPA 
production  in  plasma  to  60%.  In  combination,  SAP  (50  gg/ml) and  heparin 
synergistically delayed fibrin clot formation, and further decreased FPA produc- 
tion. These results suggest one possible mechanism by which SAP may express 
its anticoagulant capacity. 
Similar experiments were carried out in a purified system composed of human 
fibrinogen, thrombin,  SAP, and  heparin;  results are shown  in  Table  II.  SAP 
alone (80-150 #g/ml) failed to prolong the thrombin clot time or interfere with 
the production of FPA. Heparin alone slightly delayed development of the fibrin 
clot but did not alter FPA release. In combination, SAP and heparin synergisti- 
cally  (but  minimally)  prolonged  the  onset  of fibrin  formation,  but  did  not 
interfere with the release of FPA. These data are in stark contrast to the results 
observed in plasma (Figs.  1-4, Table I). 
The substantial differences observed between plasma and the purified com- 
ponent system suggested that additional plasma constituent(s), perhaps a natural 80 
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FIGURE 5.  Effect of SAP and heparin on fibrinolysis in normal plasma. 
NORMAL  PLASMA 
+ HEPARIN  =.- ....  .4 
(0.2  pg/ml) 
+ SAP  o-  ..... 
(50  pg/ml) 
*  SAP/HEP.  A  .~ 
TABLE  I 
Effects of SAP and Heparin on Thrombin Clot Time, Release of Fibrinopeptide A in Plasma, and 
Thrombin Activity* 
Thrombin  Plasma  *  Clot times  Released FPA  activity 
s  #g/ml  U/ml 
Control  23.9  15 (100%)  0.22 
+  SAP (50 #g/ml)  26.8  16 (106%)  0.27 
+  SAP (200 ug/ml)  56.8  11  (75%)  0.29 
+  Heparin (0.8 U/ml)  48.2  9  (60%)  0.17 
+  SAP (50 #g/ml) Heparin  200.0  5  (32%)  0.25 
(0.8 U/ml) 
* Clotting assay  and  FPA  were performed  with  dilute  normal  pooled plasma,  whereas  thrombin 
activity was measured in Tris-NaCI-CaCl2 pH 7.4, using a chromogenic substrate. 
* Clotting assay  and  FPA were carried out with 0.1  ml of plasma mixed with 0.4 ml of Tris-NaC1- 
CaCI~ buffer pH 7.4, or SAP/heparin. 774  SERUM  AMYLOID  P  COMPONENT  AND BLOOD  COAGULATION 
TABLE  II 
Effect of SAP, Heparin on SAP/Heparin  on the Release of 
Fibrinopeptide A in a PurEed System 
Fibrinogen*  Clot time  FPA released  * 
s  ug/ml 
Control  62.9  4.1 
+ SAP (80 #g/ml)  58.5  3.9 
+ SAP (150 #g/ml)  60.9  4.2 
+ Heparin (1 U/ml)  78.0  3.9 
+ SAP (80 #g/ml)  98.3  4.4 
Heparin (1 U/ml) 
+ SAP (150 #g/ml)  93.0  4.4 
Heparin (1 U/ml) 
* Fibrinogen was used at 600 #g/ml. 
The proteolytic action of thrombin was stopped at 60 s by transferring 
tubes into ice-water bath. 
inhibitor  of thrombin  in plasma,  might play a  role in the anticoagulant  activity 
of physiological  concentrations  of SAP.  Indeed,  the  addition  of AT-III  and 
heparin  (neither alone) or of hirudin,  an exogenous thrombin inhibitor to these 
component systems, "reconstituted"  the substantial anticoagulant  synergism be- 
tween  SAP and  heparin.  These  data  suggest that  the  expression  of inhibitory 
effects of physiological concentrations of SAP probably requires the restriction 
of thrombin  activity.  As supraphysiological  amounts of SAP (200-300  ug/ml) 
demonstrate an independent ability to inhibit clot formation and FPA release in 
plasma  in  the  absence  of  heparin  (Table  I),  these  data  imply  separate  but 
synergistic phenomenon.  However, the ability of a  low concentration  of SAP in 
the presence of heparin to minimally inhibit clot formation in isolated component 
systems in the absence of thrombin  inhibitors (Table II), indicates the presence 
of an additional mechanism. 
Effects of SAP on the Process of Fibrin Polymerization.  The final stage of fibrinogen 
transformation  involves  the  spontaneous  polymerization  of fibrin.  Upon  the 
release  of fibrinopeptide  A  and  B, both  end-to-end  and  lateral  associations of 
fibrin monomers occur to form a  noncovalently bonded gel (37).  The effect of 
SAP on fibrin  polymerization  was evaluated by determining  the time required 
for the transformation  of the soluble fibrin monomer into the clot. 
The  effect of SAP  on  the  process  of spontaneous  polymerization  of fibrin 
monomer is shown, in part,  in Table III, and more completely in Fig. 6.  In the 
control, soluble fibrin monomer polymerized in 365 s (_+ SD 26s). SAP (25-150 
#g/ml) did not interfere with normal fibrin polymerization; heparin (0.5 U/ml) 
also generated no inhibition  of the polymerization process. However, in combi- 
nation, SAP (50 #g/ml) and heparin provided a substantial synergistic inhibition 
of polymerization (Fig. 6). 
These data illustrate prevention by SAP of spontaneous fibrin polymerization 
in  the  presence  of  heparin,  and  along  with  the  ability  of SAP/heparin  to 
synergistically delay fibrinogen-fibrin  conversion, provides a second mechanisrfi 
by which SAP can participate as an anticoagulant. KU AND FIEDEL  775 
TABLE  III 
Selected Data Illustrating  the Effect of SAP and Heparin  on the Polymerization of Fibrin 
Fibrin monomer  Polymerization  time  Range  Increase* 
s 
Control  365  335-409 
+  SAP (50 #g/ml)  369  304-438 
+  Heparin (0.5 U/ml)  371  316-389 
+  SAP (50 #g/ml)  505  460-578 
Heparin (0.5 U/ml) 
+  Heparin (1  U/ml)  422  416-429 
+  SAP (50 #g/ml)  536  476-610 
Heparin (1  U/ml) 
% 
100 
101 
101 
138 
115 
147 
* SAP and heparin were added to the 
of fibrin at 37°C water-bath. 
Control value set at 100%. 
soluble fibrin monomer before the initiation of polymerization 
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FW,  URE  6.  Comparison of fibrin monomer polymerization time in the presence or absence 
of SAP  and  heparin.  The  dotted  area  represents  normal  ranges  of polymerization  time, 
whereas the striped bars represent prolonged polymerization time. 
Discussion 
SAP at  supra-physiological concentrations (150-300  #g/ml)  inhibits  the co- 
agulation  system (Table  I  and reference  17).  The data  presented herein also 
provide evidence that SAP, at physiological concentrations (5-.50 #g/ml), mark- 
edly decreases the efficacy of both the intrinsic and extrinsic coagulation pathways 
in the presence of heparin. The inability of SAP to enhance the heparin cofactor 
activity of antithrombin III shows this not to be the mechanism of increased anti- 
coagulant action.  Likewise,  the inability of SAP or SAP/heparin to  influence 
Factor  XIIIa  activity and  the presence of enhanced anticoagulant activity in 
Factor XIII deficient plasmas incubated with SAP/heparin, indicates the absence 776  SERUM AMYLOID  P COMPONENT  AND BLOOD COAGULATION 
of a  direct contribution  by Factor XIII.  In reviewing other reactions that are 
involved in the final stages of blood coagulation, an altered fibrinolytic system 
could also result in a delayed onset of fibrin clot formation. To test this possibility, 
the effect of SAP and heparin on the normal process of fibrinolysis was evaluated. 
These studies provided no evidence for an influential participation of SAP and/ 
or heparin in fibrinolysis. These data collectively focused our attention on the 
molecular events involved in the transformation of fibrinogen to fibrin, and the 
subsequent spontaneous polymerization reaction. 
The overall process of fibrinogen transitions can be summarized as follows: 
Thrombin +  Ca  +* 
Fibrinogen ~---"""~FPA  ~ nF  ~  Fn  ~ Fibrin 
~FPB 
(1)  (2)  (3) 
where FPA is fibrinopeptide A, FPB is fibrinopeptide B, nF is fibrin monomer, 
and Fn is the intermediate polymer. 
Thrombin  is  involved  in  step  1  to  activate  fibrinogen;  steps  2  and  3  occur 
spontaneously. The effect of SAP on step  1 was evaluated by monitoring the 
proteolytic action of thrombin as assessed by the thrombin clot time of plasma, 
the release of fibrinopeptide A from fibrinogen and the cleavage of p-nitroaniline 
from  a  chromogenic substrate.  The  anticoagulant  activity  of SAP  or  SAP/ 
heparin was found to be directly associated with reduction in the generation of 
fibrinopeptide A. In isolated component systems containing fibrinogen, throm- 
bin, and SAP, the synergistic amplification in the reduction of FPA production 
was observed only when heparin/anti-thrombin III (not either alone) or hirudin 
was added to  the system. These data  suggest that  SAP and heparin  function 
independently, but that restricted thrombin activity is essential for physiological 
concentrations of SAP  (5-50  #g/ml)  to  inhibit  blood  coagulation.  This  may 
explain why supraphysiological concentrations of SAP (150-300  ~g/ml) alone 
inhibit coagulation, i.e., there is a lessened requirement for restricted thrombin 
activity. 
The mechanism(s) by which SAP inhibits  FPA release remains unclear, but 
might reflect an interaction between SAP and fibrinogen that renders fibrinogen 
resistant to proteolysis. This would delay the onset of fibrin formation since FPA 
release is essential for the initial end-to-end fibrin aggregation (35).  At present, 
we have two lines of evidence (38) that support this interactive hypothesis. First, 
~2"~I-SAP is rapidly incorporated into a forming fibrin clot; second, SAP interacts 
physically with fibrinogen when measured nephelometrically. 
SAP or heparin did not individually interfere with spontaneous fibrin polym- 
erization, whereas, in combination, they synergistically prevented fibrin polym- 
erization. Thus, the ability of SAP and heparin to directly inhibit spontaneous 
fibrin  polymerization provides  a  second anticoagulative process.  The  mecha- 
nism(s) by which SAP  and  heparin  inhibit  fibrin  polymerization also  remains 
unclear,  but  several  possibilities  exist.  First,  two  fibrin  intermediates  in  the 
polymerization process have been identified (35, 39), and formation of the fibrin 
clot can by delayed or prevented by stabilizing these intermediates (40).  SAP 
and heparin, in combination, may interact with the intermediate polymers and 
stabilize them. KU AND FIEDEL  777 
Second,  it  has  been  proposed  that  during  spontaneous  polymerization  the 
release  of fibrinopeptides  from  the  central  nodule  of fibrinogen  allows  for 
intermolecular contact between that central nodule and the terminal nodules of 
neighboring molecules. Upon release of FPA, newly exposed N-terminals of the 
a  chain serve as the principal site for spontaneous polymerization (41).  SAP/ 
heparin may thus prevent spontaneous polymerization by masking these newly 
exposed N-termini. 
Third, the zeta potential may play an important role. The zeta potential is an 
expression of the electrostatic difference in  potentials  between the molecular 
surfaces of the vessel wall, blood elements and plasma proteins, such as fibrinogen 
and fibrin (42). The human fibrinogen molecule has ~26 more negative charges 
than  positive  charges  (43).  The  removal  of two  pairs  of FPA  molecules by 
thrombin reduces the excess negative charges in the central nodule from -8 to 
-1 (43). When a pair of fibrinopeptide B molecules is released, the central nodule 
has a  +5  net charge (43).  Each of the terminal nodules now has a  -4  charge 
(43).  This  is  compatible with  each  terminal  nodule  having a  complementary 
electrostatic interaction with a positively charged central nodule during sponta- 
neous  polymerization.  However,  in  the  presence  of  SAP  and  heparin,  this 
complementary electrostatic interaction may be disrupted.  Heparin is a  highly 
negatively charged polysaccharide, and is known to alter the zeta potential  of 
fibrinogen and fibrin (42). It is conceivable that SAP and heparin may contribute 
a  large  quantity  of negative  charges  to  the  terminal  nodule  of fibrin,  thus 
increasing repulsive forces. At the same time, SAP and heparin might neutralize 
the positive charges in the central nodule of the fibrin monomer. 
The potential in vivo relevance of these observations is found in the distribution 
of SAP and heparin  (-like) components in  the body.  SAP is a  normal plasma 
component in man. Recently a molecule antigenically identical to SAP has been 
shown to be an integral part of normal vascular basement membranes (15), and 
to be distributed in the peripheral microfibrillar mantle of elastic fibers in normal 
skin and blood vessels (16).  Heparin has been isolated from various organs and 
is known to be present in the granules of mast cells and basophils. Free heparin 
can also be found in the blood circulation of patients under anticoagulant drug 
therapy. Recently, heparan sulfate, a  chemical derivative of heparin, has been 
found  on  a  variety  of cell  surfaces  including  the  endothelium  (44,  45),  and 
platelets (46).  Heparan  sulfate has been reported to possess some heparinlike 
properties including the ability to inhibit blood coagulation (47, 48). Interactions 
among these  substances  would  likely occur at  blood-surface interfaces where 
many of the enzymes involved in blood coagulation are generated. Thus, SAP 
and heparin (or heparin-like substances) could be critically placed to delay or 
prevent fibrin clot formation. By analogy, since SAP and heparin (or heparin- 
like materials) have been found associated with (or in) vessel wails,  their unique 
anticoagulant  activities  might  present  a  critical  barrier  against  an  activated 
coagulation state. We suggest that these activities provide a crucial link between 
thrombo-resistant surface properties and the coagulability of blood. 778  SERUM  AMYLOID P  COMPONENT  AND BLOOD COAGULATION 
Summary 
Serum  amyloid P-component (SAP)  is  a  normal  plasma  constituent in  man 
with a circulating concentration of ~,40 ug/ml. Supraphysiological amounts of 
SAP  (150-300  /~g/ml)  have  been  reported  to  affect  coagulation.  We  have 
investigated this further by studying the effect of SAP upon clot times in both 
the absence and presence of heparin, a  suggested ligand for SAP and itself a 
modulator of coagulation processes. In the absence of heparin, SAP (5-125 ug/ 
ml) had no effect on clot times generated by Activated Thrombofax Reagent, 
brain  thromboplastin,  Russell's  Viper  Venom  or  thrombin  when  assessed  in 
normal citrated plasma.  However, in the presence of amounts of heparin that 
had only a  minor effect upon clot times, SAP (5-40 #g/ml) greatly prolonged 
clot formation, with the thrombin time the most sensitive to SAP. This suggested 
that the primary effect of SAP was at this distal level of the coagulation pathway. 
Evaluation by radioimmunoassay revealed that supraphysiological concentra- 
tions of SAP (150-300  #g/ml) alone reduced by ~25%  the release of fibrino- 
peptide A (FPA) from fibrinogen. In the presence of heparin, substantial syner- 
gism  was  observed  with  maximal  reductions  of  "-,70%  in  FPA  production 
requiring  only  25-50  #g/ml  SAP.  This  inhibition  correlated  with  increased 
thrombin clot  time but  was  unrelated to any direct  modulation in either  the 
activities of anti-thrombin III or activated Factor XIII, and was independent of 
an alteration in the rate of fibrinolysis. Further, while SAP itself  did not interfere 
with the process of spontaneous fibrin polymerization, in the presence of heparin 
a prolonged polymerization time (>145%) was observed. We believe that these 
data  reflect  the  primary  mechanisms by  which  serum  amyloid P  component 
influences blood coagulation. 
The authors wish to thank Henry Gewurz, whose insights made this endeavor possible. 
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